Fennec Pharmaceuticals（FENC）株式概要
フェネック・ファーマシューティカルズ・インクは米国でコマーシャルステージのバイオ医薬品会社として活動している。 詳細
FENC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fennec Pharmaceuticals Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$9.97 |
| 52週高値 | US$10.27 |
| 52週安値 | US$5.65 |
| ベータ | 0.91 |
| 1ヶ月の変化 | 52.45% |
| 3ヶ月変化 | 14.07% |
| 1年変化 | 25.09% |
| 3年間の変化 | 35.65% |
| 5年間の変化 | 44.28% |
| IPOからの変化 | -91.21% |
最新ニュース
分析記事 • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
ナラティブの更新 • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).Recent updates
分析記事 • May 17
We're Not Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...ナラティブの更新 • May 14
FENC: Expanding Cisplatin Ototoxicity Protection Use Will Support Future Bullish Earnings Multiple
Analysts have maintained their $18.00 price target on Fennec Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view unchanged. What's in the News Four abstracts on PEDMARK are set to be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, focusing on cisplatin related hearing loss and real world outcomes in patients receiving platinum based chemotherapy (Key Developments).ナラティブの更新 • Apr 25
FENC: Expanding Cisplatin Ototoxicity Use Should Support Future Bullish Earnings Multiple
Analysts have adjusted their price target on Fennec Pharmaceuticals to $18.00, with the change supported by updated assumptions around revenue growth, profit margins, and a future P/E of about 12.8, in line with a recently bullish initiation from Street research. Analyst Commentary Bullish analysts are framing the updated US$18.00 price target as consistent with expectations for Fennec Pharmaceuticals to execute against current revenue and margin assumptions while trading on a P/E of about 12.8. These views generally point to a setup where, if the company delivers on its plan, the current valuation case remains intact and could support the new target level.ナラティブの更新 • Apr 10
FENC: Cisplatin Ototoxicity Niche Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $18.00, supported by updated assumptions on revenue growth, profit margin and future P/E, and underpinned by a recent bullish initiation from B. Riley that reflects growing confidence in the company’s outlook.ナラティブの更新 • Mar 27
FENC: Cisplatin Ototoxicity Niche Will Underpin Future Supportive Care Upside
Analysts have reaffirmed an $18 price target for Fennec Pharmaceuticals, highlighting supportive research that emphasizes Pedmark's role as a unique, approved option in oncology supportive care. They are also reassessing assumptions related to future revenue growth, profit margins and P/E expectations.
ナラティブの更新 • Mar 11
FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential
Narrative Update: Fennec Pharmaceuticals Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.ナラティブの更新 • Feb 25
FENC: Cisplatin Ototoxicity Niche Will Support Future Oncology Care Upside
Analysts are reiterating an $18 price target for Fennec Pharmaceuticals. They point to updated assumptions that include slightly lower discount rates, higher projected revenue growth and profit margins, and a modestly lower future P/E, supported by recent bullish initiations that highlight Pedmark's role as a unique oncology supportive care opportunity.ナラティブの更新 • Feb 10
FENC: Cisplatin Ototoxicity Niche Will Drive Future Supportive Care Upside
Analysts have reiterated a US$18 price target on Fennec Pharmaceuticals, supported by their view that Pedmark offers a unique, only-approved option in oncology supportive care, with what they describe as realistic peak U.S. sales potential above US$300m. Analyst Commentary Recent coverage has centered on Pedmark as a key driver for Fennec's equity story, with bullish analysts highlighting its role as the only approved agent for reducing the risk of cisplatin induced ototoxicity in oncology supportive care.ナラティブの更新 • Jan 26
FENC: Cisplatin Ototoxicity Leadership And New Studies Will Support Strong Future Upside
Narrative Update Analysts are reaffirming a US$18 price target on Fennec Pharmaceuticals, pointing to Pedmark's role as the only approved agent for reducing cisplatin induced ototoxicity and noting that they view U.S. peak sales potential above US$300m as realistic. Analyst Commentary Bullish analysts are highlighting Fennec Pharmaceuticals as a focused oncology supportive care story, built around Pedmark as an intravenous formulation of sodium thiosulfate for reducing the risk of cisplatin induced ototoxicity.ナラティブの更新 • Jan 12
FENC: Unique Oncology Supportive Care Opportunity Will Drive Stronger Future Upside Potential
Narrative Update Overview Our fair value estimate for Fennec Pharmaceuticals edges up from $17 to $18 per share, reflecting analysts' view that Pedmark offers a unique oncology supportive care opportunity with U.S. peak sales potential cited north of $300 million and supports using a slightly higher revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts are centering their thesis on Pedmark as a differentiated oncology supportive care product, and that view is shaping how they think about valuation, execution risk, and long term growth potential.ナラティブの更新 • Dec 27
FENC: Expanded Adult Study Will Drive Stronger Future Upside Potential
Analysts have nudged their price target on Fennec Pharmaceuticals modestly higher to reflect slightly faster expected revenue growth, marginally improved profit margins, and a marginally lower projected future price to earnings multiple, supporting a fair value estimate of $17.00 per share. What's in the News Planned City of Hope investigator sponsored study will evaluate PEDMARK for preventing cisplatin induced hearing loss in adult men with stage II III metastatic testicular germ cell tumors, expanding its potential use beyond pediatrics (company announcement).Seeking Alpha • Dec 22
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Summary Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling cancer. Pedmark is FDA-approved for pediatric patients ≥1 month, and it has shown good efficacy so far with patients. Pedmark is also the “first/only” in this drug class, and management believes they can eventually make Pedmark the standard-of-care to avoid hearing loss. Thus, despite FENC’s concentrated risk on Pedmark, I feel their outlook for 2026 is quite compelling. So, I rate the stock a “Buy” at these levels. Read the full article on Seeking Alphaナラティブの更新 • Dec 13
FENC: Expanded Hearing Loss Indication Will Drive Stronger Future Upside Potential
Analysts have raised their price target on Fennec Pharmaceuticals from 15 dollars to 17 dollars, citing updated assumptions for discount rates, growth, profitability, and valuation multiples that, despite being more conservative on margins and revenue growth, still imply a higher fair value. What's in the News City of Hope to launch an investigator sponsored study of PEDMARK in adult men with stage II III metastatic testicular germ cell tumors to prevent cisplatin induced hearing loss, expanding potential use beyond pediatrics (company announcement) Positive topline results reported from the Phase 2/3 STS J01 trial in Japan evaluating PEDMARK for reducing cisplatin induced ototoxicity in pediatric and AYA patients, with Fennec planning to pursue Japanese registration and potential partnering or licensing deals (company announcement) Completed 35 million dollar follow on equity offering of 4,666,667 common shares at 7.50 dollars per share, bolstering the balance sheet for commercialization and development initiatives (financing filing) Announced a non brokered private placement of 670,000 common shares at 7.50 dollars per share for expected gross proceeds of 5.0 million dollars, with closing targeted for November 17, 2025 (financing announcement) Lock up agreements put in place on over 28 million common shares and various equity linked awards through February 12, 2026, limiting insider and holder sales for 91 days after the November 13, 2025 offering (offering documentation) Valuation Changes Fair value estimate increased from 15 dollars to 17 dollars per share, implying a modest upward revision to intrinsic value despite more conservative operating assumptions.分析記事 • Apr 24
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) may be sending very bullish...分析記事 • Mar 13
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Shareholders might have noticed that Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) filed its full-year result this time...分析記事 • Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders are no doubt pleased to see that the share price has bounced...分析記事 • Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 2.5x Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is...
新しいナラティブ • Sep 28
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.分析記事 • Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Today is shaping up negative for Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) shareholders, with the analysts delivering...分析記事 • Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
The Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) share price has fared very poorly over the last month, falling by a...分析記事 • Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
With a median price-to-sales (or "P/S") ratio of close to 12.9x in the Biotechs industry in the United States, you...株主還元
| FENC | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 7.9% | -1.6% | -0.8% |
| 1Y | 25.1% | 34.4% | 27.1% |
業界別リターン: FENC過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: FENCは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。
価格変動
| FENC volatility | |
|---|---|
| FENC Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: FENCの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: FENCの 週次ボラティリティ は、過去 1 年間で9%から14%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1996 | 35 | Jeff Hackman | www.fennecpharma.com |
フェネック・ファーマシューティカルズ・インクは米国でコマーシャルステージのバイオ医薬品会社として活動している。同社の製品候補には、シスプラチン誘発性耳毒性の小児患者予防のためのチオ硫酸ナトリウム製剤であるPEDMARKがある。同社は地域の小児がん専門医や医療科学リエゾンを通じて製品を販売している。フェネック・ファーマシューティカルズ・インクは、シスプラチンをベースとした治療を受けている思春期、若年成人、成人がん患者における耳毒性のリスク軽減におけるチオ硫酸ナトリウム注射の臨床的有用性の評価について、タンパ総合病院財団（Tampa General Hospital Foundation, Inc.）およびノルジン・ファーマUK社と共同研究を行っている。同社は以前はAdherex Technologies Inc.として知られていたが、2014年9月にFennec Pharmaceuticals Inc.に社名を変更した。フェネック・ファーマシューティカルズ・インクは1996年に法人化され、ノースカロライナ州リサーチ・トライアングル・パークを拠点としている。
Fennec Pharmaceuticals Inc. 基礎のまとめ
| FENC 基礎統計学 | |
|---|---|
| 時価総額 | US$338.69m |
| 収益（TTM） | -US$8.37m |
| 売上高(TTM) | US$51.00m |
6.8x
P/Sレシオ-41.4x
PER（株価収益率FENC は割高か？
公正価値と評価分析を参照収益と収入
| FENC 損益計算書（TTM） | |
|---|---|
| 収益 | US$51.00m |
| 売上原価 | US$3.96m |
| 売上総利益 | US$47.04m |
| その他の費用 | US$55.41m |
| 収益 | -US$8.37m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.24 |
| グロス・マージン | 92.23% |
| 純利益率 | -16.42% |
| 有利子負債／自己資本比率 | 0% |
FENC の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 15:58 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Fennec Pharmaceuticals Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Naureen Quibria | Capital One Securities, Inc. |